Related Experiment Video
Updated: Oct 25, 2025
Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
Delafloxacin as a treatment option for community-acquired pneumonia infection
Cristiana M Nascimento-Carvalho1
1Department of Pediatrics, Federal University of Bahia School of Medicine, Salvador, Brazil.
Abstract:
Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality in adults. Bacterial pathogens are recognized to be frequent causative agents, which makes antibacterial treatment crucial for the evolution of these patients. There are several antimicrobial options available in daily practice. However, bacterial resistance is a problem. The chemical, pharmacokinetic, pharmacodynamics, and safety characteristics of delafloxacin, a fluoroquinolone, are discussed. The data from one phase 3 clinical trial evaluating the use of delafloxacin in adults with community-acquired pneumonia is also discussed, along with findings from other meaningful studies. In vitro data have shown that delafloxacin has broad spectrum activity. Results from phase 2 and phase 3 studies have demonstrated that delafloxacin use is safe. International guidelines have recommended respiratory fluoroquinolones as second option for non-severe cases and must be considered in very severe patients not improving to a betalactam/macrolide combination. Delafloxacin was compared to moxifloxacin in the phase 3 community-acquired pneumonia trial. Serious and life-long adverse events due to fluoroquinolones use have been recently reported. Delafloxacin may possibly replace currently available fluoroquinolones, particularly in the treatment of resistant pathogens, such as ciprofloxacin-resistant P. aeruginosa isolates when other drugs are inefficient.
Insights
Delafloxacin, a novel fluoroquinolone, shows broad-spectrum activity and a favorable safety profile for treating community-acquired pneumonia (CAP). It offers a potential alternative to existing treatments, especially for resistant bacterial infections.
Area of Science:
- Pharmacology
- Infectious Diseases
- Clinical Medicine
Background:
- Community-acquired pneumonia (CAP) is a significant cause of illness and death in adults.
- Bacterial infections are common causes of CAP, necessitating effective antibacterial treatments.
- Antimicrobial resistance poses a challenge in managing bacterial pneumonia.
Purpose of the Study:
- To discuss the characteristics of delafloxacin, a fluoroquinolone antibiotic.
- To review clinical trial data on delafloxacin for CAP treatment.
- To evaluate delafloxacin's potential role in managing resistant bacterial infections.
Main Methods:
- Review of chemical, pharmacokinetic, pharmacodynamic, and safety data for delafloxacin.
- Analysis of Phase 2 and Phase 3 clinical trial results for delafloxacin in CAP.
- Comparison of delafloxacin with moxifloxacin in a Phase 3 CAP trial.
Main Results:
- Delafloxacin exhibits broad-spectrum activity against bacterial pathogens.
- Phase 2 and 3 studies indicate delafloxacin is safe for patient use.
- Delafloxacin demonstrated efficacy comparable to moxifloxacin in a Phase 3 trial.
Conclusions:
- Delafloxacin is a safe and effective option for CAP treatment.
- International guidelines suggest respiratory fluoroquinolones as an alternative for specific CAP cases.
- Delafloxacin may be valuable for treating resistant pathogens where other antibiotics fail.
More Related Videos
07:50Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
Published on: October 25, 2024
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
Related Concept Videos
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:27Acute Pyelonephritis I: Introduction
01:17Urinary Tract Infection IV: Nursing Management
01:30Pneumonia III: Complications and Assessment
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....